Vaxart Announces Inducement Equity Awards to New Employees and Senior Vice President
South San Francisco, CA – In an effort to strengthen its team and attract top talent, Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines, announced on March 27, 2025, that the independent members of its Board of Directors granted inducement equity awards to seven new non-executive employees and to Laurie Hastings, the recently-appointed Senior Vice President of Human Resources.
Awards to New Employees
The seven new non-executive employees were granted a combined total of 292,500 shares of Vaxart’s common stock as a material inducement for them to commence employment with the company. This consisted of stock options to purchase 195,000 shares and restricted stock unit awards covering 97,500 shares.
Award to Senior Vice President
Laurie Hastings, who joined Vaxart as Senior Vice President of Human Resources, was granted a stock option to purchase 300,000 shares and a restricted stock unit award covering 67,000 shares. These awards were also granted as a material inducement for her to join the company.
Impact on Individuals
For individuals who may be considering a career at Vaxart, this news signifies the company’s commitment to attracting and retaining top talent. The sizeable equity awards granted to new employees and the Senior Vice President demonstrate the potential for significant financial gains for those who join and contribute to the company’s success.
Impact on the World
From a global perspective, this news represents another step forward in the biotech industry’s ongoing efforts to develop and commercialize innovative vaccines. As Vaxart continues to grow its team, it brings us closer to realizing the potential of oral recombinant vaccines, which could offer numerous advantages over traditional injectable vaccines.
Conclusion
With the recent inducement equity awards to new employees and the Senior Vice President, Vaxart is making strategic moves to strengthen its team and further its mission in the biotech industry. These awards not only serve as a significant incentive for individuals to join the company but also contribute to the overall progress of oral recombinant vaccine development. As Vaxart continues to grow and innovate, we can expect to see more exciting developments in the world of oral vaccines.
- Vaxart grants inducement equity awards to seven new non-executive employees and Senior Vice President Laurie Hastings
- Awards consist of stock options and restricted stock unit awards
- Inducement awards serve as a material inducement for individuals to commence employment with Vaxart
- Significant financial gains possible for employees with stock options and RSUs
- News represents another step forward in the biotech industry’s efforts to develop and commercialize innovative vaccines
